| Eligibility |
Inclusion Criteria:
1. Able to read, understand, and willing to sign an informed consent form (ICF) and
complete questionnaires written in English.
2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of
consent.
3. Smokes combustible, filtered, non-menthol or menthol cigarettes, 83 mm to 100 mm in
length. Smokers that also use other tobacco products (e.g., ENDS, smokeless tobacco,
heated tobacco products) will not be excluded from study participation.
4. Smokes an average of at least 10 cigarettes per day (CPD) and inhales the smoke, for
at least 6 months prior to Screening. Brief periods of abstinence due to illness, quit
attempt (prior to 30 days of Screening), or clinical study participation (prior to 30
days of Screening) will be allowed at the discretion of the PI.
5. Agrees to smoke the same UB cigarette throughout the study period. The UB cigarette is
defined as the reported cigarette brand style currently smoked most frequently by the
subject.
6. Expired breath carbon monoxide (ECO) level is = 10 ppm and = 100 ppm at Screening and
at check-in Day 1.
7. Positive urine cotinine test at Screening.
8. Response at Screening to the Fagerström Test for Nicotine Dependence (FTND) Question 1
("How soon after you wake up do you smoke your first cigarette?") is either "Within 5
minutes" or "6-30 minutes".
9. Willing to use UB cigarette, HTP IPs, and Nicorette nicotine gum during the study
period.
10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to the
start of each Test Session (either 5 or 6 sessions depending on the Study Arm).
11. Females must be willing to use a form of contraception acceptable to the PI from the
time of signing the informed consent until End-of-Study.
12. Agrees to an in-clinic confinement of 11 days (10 nights) for Study Arm 1 -or- 13 days
(12 nights) for Study Arm 2.
Exclusion Criteria:
1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal,
hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological
disease, or any other concurrent disease or medical condition that, in the opinion of
the PI, makes the study subject unsuitable to participate in this clinical study.
2. History, presence of, or clinical laboratory test results indicating diabetes.
3. Scheduled treatment for asthma currently or within the past consecutive 12 months
prior to the Screening Visit. As-needed treatment, such as inhalers, may be included
at the PI's discretion pending approval from the Medical Monitor.
4. History or presence of bleeding or clotting disorders.
5. Any history of cancer, except for primary cancers of skin such as localized basal
cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.
6. Systolic blood pressure of > 160 mmHg or a diastolic blood pressure of > 95 mmHg,
measured after being seated for five minutes at Screening and at check-in Day 1.
7. Weight of = 110 pounds.
8. Hemoglobin level is < 12.5 g/dL for females or < 13.0 for males g/dL at Screening.
9. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to
become pregnant during the course of the study.
10. A positive urine drug screen without evidence of prescribed corresponding concomitant
medication(s) at Screening or check-in Day 1.
11. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen
(HBsAg), or hepatitis C virus (HCV).
12. Use of any medication or substance that aids in smoking cessation, including but not
limited to any nicotine replacement therapy (e.g., nicotine gum, lozenge, patch),
varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (=)
30 days prior to signing the ICF.
13. Postpones a decision to quit using tobacco- or nicotine-containing products in order
to participate in this study or self-reports a previous attempt within (=) 30 days
prior to signing the ICF.
14. Any use of aspirin (= 325 mg/day) or anticoagulants.
15. Individuals = 35 years of age currently using systemic, estrogen-containing
contraception or hormone replacement therapy.
16. Whole blood donation within 8 weeks (= 56 days) prior to signing the ICF. NOTE:
Subjects will be advised against scheduling a whole blood donation for at least 7 days
following study completion.
17. Plasma donation within (=) 7 days prior to signing the ICF. NOTE: Subjects will be
advised against scheduling a plasma donation for at least 7 days following study
completion.
18. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or
nicotine-containing products as part of their job.
19. Participation in another clinical trial within (=) 30 days prior to signing the
informed consent. The 30-day window for each subject will be derived from the date of
the last study event in the previous study to the time of signing the ICF in the
current study.
20. Drinks more than 21 servings of alcoholic beverages per week.
21. Has a positive alcohol result at Screening or check-in Day 1.
22. Determined by the PI to be inappropriate for this study.
|
